Please assess the completion status of the following clinical trial:

Trial Title: Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* New or preexisting diagnosis of multiple myeloma~  - Smoldering or indolent multiple myeloma meeting one of the following criteria:~ * Bone marrow plasma cells ≥ 10%~ * Serum monoclonal IgG or IgA protein ≥ 3.0 g/dL OR urine monoclonal light chain ≥ 1g by 24-hour urine protein electrophoresis~* Measurable disease~* Does not require immediate chemotherapy, in the opinion of the treating physician~* No active myeloma or primary amyloidosis requiring chemotherapy or any agents that may interact with anakinra (e.g., etanercept, infliximab, or thalidomide)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0~* Total WBC ≥ 3,500/mm\^3~* ANC ≥ 1,700/mm\^3~* Creatinine ≤ 1.5 times upper limit of normal~* Able to self-inject medication or have a caregiver who can administer the drug~* Not pregnant or nursing~* Negative pregnancy test~* No acute or chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy within the past 12 weeks~* No active malignancy within the past 5 years except basal cell carcinoma of the skin or carcinoma in situ of cervix~  - Patients with a previously resected malignancy that does not require further treatment are eligible~* No New York Heart Association (NYHA) class III or IV congestive heart failure~* No rheumatoid arthritis or other diseases requiring immunosuppressive therapy~* No asthma, inflammatory bowel disease, or any debilitating physical or psychiatric illness that, in the judgment of the investigator, would interfere with the conduct of the study~PRIOR CONCURRENT THERAPY:~\* More than 30 days since prior treatment with dehydroepiandrosterone (DHEA), clarithromycin, pamidronate, steroids, or any other agent that may affect M-protein

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra with/without Dexamethasone (Type: EXPERIMENTAL): Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra.

Based on this trial design, predict the completion outcome and termination type (if applicable).